Abstract:
Atherosclerosis is the main cause of mortality and morbidity globally. Lipoprotein-associated phospholipase A2
(LpPLA2
) activity is suspected to have a significant role in atherosclerosis. 50 Sprague-Dawley Rats were divided into
five groups: normal, dyslipidemia, Type 2 diabetes mellitus (T2DM), dyslipidemia with darapladib administration
and T2DM with darapladib administration. These groups were divided into two serial times: 8 and 16 weeks.
mRNA Lp-PLA2
was measured from blood and aortic tissue extraction. Aortic tissue Lp-PLA2
was measured by
immunofluorescence. Lp-PLA2
expression in aortic tissue was consistently increased in dyslipidemia and T2DM.
The expression of Lp-PLA2
enzymatic was significantly suppressed (p < 0.05) with the administration of darapladib
especially in 8 weeks groups in both dyslipidemia and T2DM. The administration of darapladib in dyslipidemia
and T2DM didn’t significantly suppress the expression of mRNA Lp-PLA2
in blood and aortic tissue. The failure
of genetic expression suppression of Lp-PLA2
was found in both 8 weeks and 16 weeks groups. The expression of
Lp-PLA2
protein also showed an inclined difference between dyslipidemia and T2DM. These results showed that
administration of darapladib significantly decreased Lp-PLA2
protein but prone to increase the expression of mRNA
Lp-PLA2 in blood and aortic tissue in dyslipidemia and T2DM model
